Canine Separation Anxiety Treatment Market (2021 - 2031)
Canine Separation Anxiety Treatment Market By Drug Molecule (Amitriptyline, Buspirone, Clomipramine), By Anxiety Type (Aggressive anxiety, Non-aggressive anxiety), By Distribution Channel - Global Market Insights 2021 to 2031
Core Findings
FREE CustomizationCanine Separation Anxiety Treatment Market Outlook
Canine separation anxiety treatment market analysis shows that global market value enjoyed year-on-year (YoY) growth of 5.4% in 2021, with the market valued at US$ 22.45 Mn.
Value of aggressive anxiety treatment is expected to increase to US$ 26.13 Mn, while that of non-anxiety treatment to US$ 13.85 Mn in 2031.
Key Points Covered in Canine Separation Anxiety Treatment Industry Survey:
- Market Estimates and Forecasts (2016-2031)
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise and Region-wise Analysis
- Competition Mapping and Benchmarking
- Market Share Analysis
- COVID-19 Impact on Canine Separation Anxiety Treatment and How to Navigate
- Recommendation on Key Winning Strategies
Industry Analysis of Canine Separation Anxiety Treatment from 2016 to 2020 Compared to Demand Outlook for 2021 to 2031
According to Fact.MR - a market research and competitive intelligence provider, in 2020, the global canine separation anxiety treatment market was valued at US$ 21.4 Mn in 2020, and has been expanding at a CAGR of 4.3% over the past years. High prevalence of canine anxiety rising high adoption of canines are primary factors contributing to growth of the market.
On the other hand, the current COVID-19 pandemic has led to a moderate negative impact on the sales of canine separation treatment drugs. As more pet owners have been working from home during this time frame (2020 to 2021), separation anxiety issues have lessened to a great extent.
However, with the relaxation of lockdown curbs and commencement of vaccination drives, most pet parents will return to work. This increases the chances of developing separation anxiety disorders among canines, and thus creates demand for drugs to calm them down.
Overall, the market of medication for separation anxiety is expected to expand at around 6% CAGR through 2031.
Are Limited Number of Approved Drugs Impacting Growth of the Canine Separation Anxiety Treatment Industry?
Considering the global prevalence of canine separation anxiety, lesser number of drugs are approved. The U.S. FDA has approved only two prescription drugs that are used specifically to treat canine separation anxiety. Clomipramine (Elanco Animal Health) and fluoxetine hydrochloride (Reconcile, Pegasus Laboratories, Inc.) are approved for treating the behavioural disorder.
Will High Cost of Veterinary Care Hamper Demand for Canine Separation Anxiety Treatment?
Despite the growing trend of pet care insurance, the number of pets covered for treatment is very low. Consequently, pet parents have to bear with majority of the cost of treatment, including routine visits, surgeries, and other health conditions.
One of the primary causes for increase in veterinarian expenses is that medicine technology has progressed. Moreover, every pet, be it a dog or cat, has their own unique personality and independent needs. Also, if a pet owner has dogs two of different breeds, it requires different medical attention. This is yet another factor responsible for rise in veterinary costs.
Also, some medicines are required to be taken by the pet for an extended amount of time or even throughout their life, and this quickly adds up to the overall medication cost.
What are the Key Opportunities for Stakeholders in Canine Separation Anxiety Treatment?
Overall cost of treating canine separation anxiety is significantly higher with branded drugs, and is anticipated to remain higher, especially when compared with generic or other extra-label/off-label drugs. These higher costs have driven demand of lower cost treatment alternatives. For example, demand for diazepam for canines has seen a gradual decrease over the years.
Also, some of the approved drugs such as Clomipramine have lost their patent, which had led to the development of generic versions. Thus, demand for lower cost alternatives are expected to create lucrative opportunities for players operating in the canine separation anxiety treatment space. Sales of amitriptyline for dogs have been witnessing a decrease over the years. Similarly, demand for amitriptyline for dogs has also been affected.
Country-wise Analysis
What Makes the U.S. a Large Market for Canine Separation Anxiety Treatment?
The canine separation anxiety treatment industry survey for the U.S. estimates that the market topped US$ 6.4 Mn in 2020. Growth is attributed to high number of dogs suffering from canine separation anxiety in the country.
Canines suffering from separation anxiety are very attached to their owners and get extremely disturbed when left alone. In response to this, they show aggressive behavior.
Approximately 13 million dogs in the U.S. suffer from canine separation anxiety, which has a huge impact on their quality of life and long-term health. Thus, high number of dogs suffering from canine separation anxiety will drive he demand for medications to calm their aggressive behavior, which is anticipated to drive market in the country.
How is Canine Separation Anxiety Treatment Demand Outlook Shaping in China?
The market in China is anticipated to reach US$ 6.8 Mn by 2031, and is expected to expand at a CAGR of 7% over the forecast period. High adoption of canines as compared to other pets in China is one of the primary factors creating a positive impact on market growth. According to a Chinese pet industry whitepaper, in 2019, overall, 55 million canines were adopted as compared to 44.1 million cats.
Greater adoption of canine population is expected to drive demand for canine healthcare and medication services, including the treatment for separation anxiety.
Category-wise Insights
Why is Clomipramine to Most Preferred Drug Used to Treat Canine Separation Anxiety?
Clomipramine is expected to be the most preferred type of drug used to treat canine separation anxiety. Also, Clomipramine is the most effective in reducing separation-related behavior by calming anxiety issues.
Clomipramine, when administered at a dosage of 1mg/kg at a 12-hour interval, increases passive behavior and reduces pacing scratching and whining of dogs in absence of its owner. Also, when the dosage is increased to 2mg/kg every 12 hours, it produces additional improvements and promotes more passive behavior when dogs are left alone.
Owing to these benefits, demand for Clomipramine is growing among veterinarians to treat canine separation anxiety issues, thus capturing the largest share in the market by drug molecule.
How Big is the Opportunity for Online Veterinary Pharmacies for Canine Separation Anxiety Treatment?
The distribution structure of veterinary drugs is changing as the Internet becomes more widely accessible around the world. The number of online veterinary pharmacies is growing, as pet owners increasingly use the Internet to research disease signs and place orders for over-the-counter (OTC) drugs as well as prescription drugs.
Also, certain compounding pharmacies provide doorstep deliveries of vet medicines after receiving online orders. This trend is most common in the U.S., Europe, and Pacific countries, owing to the availability of online catalogues for prescription drugs.
Moreover, to capitalize on the growth opportunities, venture capital firms are investing in e-Commerce to provide dispensing services to pet owners.
In this regard, Vets First Choice, in July 2017, raised US$ 223 million to introduce its new innovative services and expand its offerings in the European and Asian markets. The Vets First Choice platform enables practitioners to track medication and service compliance as well as connect clients proactively to solve unmet pet care needs.
Additionally, Vets First Choice uses an e-Commerce platform to help veterinarians compete with larger online competitors by facilitating medicine dispensing to pet owners.
PetCareRx (US), Wedgewood Pharmacy (US), Pet Care Pharmacy (Australia), 365Vet (UK), and Petdrugsonline (UK) are some of online pharmacies offering medications for canine separation anxiety.
Thus, online availability of canine medicines provides an array of opportunities for market growth.
Insights into Canine Separation Anxiety Treatment Market Competition Analysis
Market players involved in canine separation anxiety treatment are engaged in expanding their regional presence through acquisitions, collaborations, expansions, product launches, and strengthening their existing distribution network.
- In August 2019, Zoetis acquired Platinum Performance, a nutrition-focused animal health business, which offers its nutritional products formulas for dogs, cats, and horses.
- In October 2019, Zoetis acquired Phoenix Lab, a leading veterinary reference laboratory, to enhance its offerings in veterinary diagnostic space.
- In November 2016, Pegasus Laboratory (PRN Pharmacal) acquired Veterinary Products Laboratories (VPL) animal health, which focused on providing veterinary products for companion animals.
Report Scope
| Attribute | Details |
|---|---|
| Forecast Period | 2021 to 2031 |
| Historical Data Available for | 2016 to 2020 |
| Market Analysis | US$ Mn for Value |
| Key Regions Covered | North America; Latin America; Europe; MEA; East Asia; South Asia; Oceania |
| Key Countries Covered | US, Canada, Brazil, Mexico, Germany, U.K., France, Spain, Italy, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, South Africa, GCC Countries, Turkey, GCC Countries |
|
Key Market Segments Covered |
Drug Molecule, Anxiety Type, Distribution Channel, Region |
|
Key Companies Profiled |
Elanco Animal Health; Pegasus Laboratories Inc. (PRN Pharmacal); Zoetis Inc.; Pfizer Inc.; Virbac SA; Mizner Bioscience LLC; Dechra Pharmaceuticals PLC; Teva Pharmaceutical Industries Ltd.; Apotex Inc. |
|
Pricing |
Available upon Request |
Key Market Segments Covered in Canine Separation Anxiety Treatment Industry Research
-
By Drug Molecule:
- Alprazolam (XanaX)
- Amitriptyline
- Buspirone
- Clomipramine
- Dexmedetomidine
- Diazepam (Valium)
- Fluoxetine Hydrochloride
- Others
-
By Anxiety Type:
- Aggressive
- Non-Aggressive
-
By Distribution Channel:
- through Veterinary Hospitals
- through Veterinary Clinics
- through Pharmacies & Drug Stores
- through Online Pharmacies
Table of Content
- 1. Executive Summary
- 2. Market Overview
- 3. Market Context
- 4. Market Background
- 5. Global Market Value (Size US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031
- 6. Global Market Value (Size US$Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Molecule
- 6.1. Alprazolam (Xanax)
- 6.2. Amitriptyline
- 6.3. Buspirone
- 6.4. Clomipramine
- 6.5. Dexmedetomidine
- 6.6. Diazepam (Valium)
- 6.7. Fluoxetine Hydrochloride
- 6.8. Others
- 7. Global Market Value (Size US$Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Anxiety Type
- 7.1. Aggressive Anxiety
- 7.2. Non to Aggressive Anxiety
- 8. Global Market Value (Size US$Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
- 8.1. Veterinary Hospitals
- 8.2. Veterinary Clinics
- 8.3. Pharmacies & Drug Stores
- 8.4. Online Pharmacies
- 9. Global Market Value (Size US$Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Region
- 9.1. North America
- 9.2. Latin America
- 9.3. Europe
- 9.4. South Asia
- 9.5. East Asia
- 9.6. Oceania
- 9.7. Middle East & Africa (MEA)
- 10. North America Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 11. Latin Americ Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 12. Europe Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 13. South Asia Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 14. East Asia Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 15. Oceania Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 16. Middle East & Africa Market Analysis 2016 to 2020 and Forecast 2021 to 2031
- 17. Key and Emerging Countries Market Analysis 2016 to 2020, and Forecast 2021 to 2031
- 18. Market Structure Analysis
- 19. Competition Analysis
- 19.1. Zoetis Inc.
- 19.2. Elanco Animal Health, Inc.
- 19.3. Pegasus Laboratory Inc.
- 19.4. Teva Pharmaceutical Industries
- 19.5. Pfizer Inc.
- 19.6. Apotex Inc.
- 19.7. Virbac SA
- 19.8. Minzer Bioscience LLC
- 19.9. Dechra Pharmaceuticals PLC
- 20. Assumptions & Acronyms
- 21. Research Methodology
List Of Table
Table 01: Global Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Molecule
Table 02: Global Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Anxiety Type
Table 03: Global Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 04: Global Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Region
Table 05: North America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Molecule
Table 06: North America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Anxiety Type
Table 07: North America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 08: North America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 09: Latin America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Molecule
Table 10: Latin America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Anxiety Type
Table 11: Latin America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 12: Latin America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 13: Europe Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Molecule
Table 14: Europe Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Anxiety Type
Table 15: Europe Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 16: Europe America Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 17: South Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Molecule
Table 18: South Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Anxiety Type
Table 19: Europe Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 20: South Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 21: East Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Molecule
Table 22: East Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Anxiety Type
Table 23: East Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 24: East Asia Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 25: Oceania Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Molecule
Table 26: Oceania Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Anxiety Type
Table 27: Oceania Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 28: Oceania Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
Table 29: Middle East & Africa Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Drug Molecule
Table 30: Middle East & Africa Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Anxiety Type
Table 31: Middle East & Africa Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Distribution Channel
Table 32: Middle East & Africa Market Size (US$ Mn) Analysis 2016 to 2020 and Forecast 2021 to 2031, By Country
List Of Figures
Figure 01: Global Market Revenue Share by Drug Molecule, 2021E & 2031F
Figure 02: Global Market Revenue Share by Type of Anxiety, 2021E & 2031F
Figure 03: Global Market Revenue Share by Distribution Channel, 2021E & 2031F
Figure 04: Global Anxiety Market Historical Market Value and Y-o-Y, 2016 to 2020
Figure 05: Global Market Value (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 06: Global Market Absolute $ Opportunity, 2021 to 2031
Figure 07: Global Market Share Analysis (%) By Drug Molecule, 2021 & 2031
Figure 08: Global Market Y-o-Y Growth (%) By Drug Molecule, 2021 to 2031
Figure 09: Global Market Attractiveness Analysis, By Drug Molecule
Figure 10: Global Market Share Analysis (%) By Anxiety Type, 2021 & 2031
Figure 11: Global Market Y-o-Y Growth (%) By Anxiety Type, 2021 to 2031
Figure 12: Global Market Attractiveness Analysis, By Anxiety Type
Figure 13: Global Market Share Analysis (%) By Distribution Channel, 2021 & 2031
Figure 14: Global Market Y-o-Y Growth (%) By Distribution Chanel, 2021 to 2031
Figure 15: Global Market Attractiveness Analysis, By Distribution Channel
Figure 16: Global Market Share Analysis (%) By Region, 2021 & 2031
Figure 17: Global Market Y-o-Y Growth (%) By Region, 2021 to 2031
Figure 18: Global Market Attractiveness Analysis, By Region
Figure 19: North America Anxiety Market Share, By Drug Molecule (2021)
Figure 20: North America Market Share, By Anxiety Type (2021)
Figure 21: North America Market Share, By Distribution Channel (2021)
Figure 22: North America Market Share, By Country (2021)
Figure 23: North America Canine Market size (US$ Mn) 2021 & 2031
Figure 24: North America Market Value (US$ Mn) Analysis, 2016 to 2020
Figure 25: North America Market Value (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 26: North America: Market Attractiveness Analysis by Drug Molecule, 2021 to 2031
Figure 27: North America: Market Attractiveness Analysis by Anxiety Type 2021 to 2031
Figure 28: North America: Market Attractiveness Analysis by Distribution Channel, 2021 to 2031
Figure 29: North America: Market Attractiveness Analysis by Country, 2021 to 2031
Figure 30: Latin America Anxiety Market Share, By Drug Molecule (2021)
Figure 31: Latin America Market Share, By Anxiety Type (2021)
Figure 32: Latin America Market Share, By Distribution Channel (2021)
Figure 33: Latin America Market Share, By Country (2021)
Figure 34: Latin America Canine Market size (US$ Mn) 2021 & 2031
Figure 35: Latin America Market Value (US$ Mn) Analysis, 2016 to 2020
Figure 36: Latin America Market Value (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 37: Latin America Market Attractiveness Analysis by Drug Molecule, 2021 to 2031
Figure 38: Latin America Market Attractiveness Analysis by Anxiety Type 2021 to 2031
Figure 39: Latin America: Market Attractiveness Analysis by Distribution Channel, 2021 to 2031
Figure 40: Latin America: Market Attractiveness Analysis by Country, 2021 to 2031
Figure 41: Europe Anxiety Market Share, By Drug Molecule (2021)
Figure 42: Europe Market Share, By Anxiety Type (2021)
Figure 43: Europe Market Share, By Distribution Channel (2021)
Figure 44: Europe Market Share, By Country (2021)
Figure 45: Europe Market size (US$ Mn) 2021 & 2031
Figure 46: Europe Market Value (US$ Mn) Analysis, 2016 to 2020
Figure 47: Europe Market Value (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 48: Europe: Market Attractiveness Analysis by Drug Molecule, 2021 to 2031
Figure 49: Europe: Market Attractiveness Analysis by Anxiety Type 2021 to 2031
Figure 50: Europe Market Attractiveness Analysis by Distribution Channel, 2021 to 2031
Figure 51: Europe Market Attractiveness Analysis by Country, 2021 to 2031
Figure 52: South Asia Anxiety Market Share, By Drug Molecule (2021)
Figure 53: South Asia Market Share, By Anxiety Type (2021)
Figure 54: South Asia Market Share, By Distribution Channel (2021)
Figure 55: South Asia Market Share, By Country (2021)
Figure 56: South Asia Canine Market size (US$ Mn) 2021 & 2031
Figure 57: South Asia Market Value (US$ Mn) Analysis, 2016 to 2020
Figure 58: South Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 59: South Asia Market Attractiveness Analysis by Drug Molecule, 2021 to 2031
Figure60: South Asia Market Attractiveness Analysis by Anxiety Type 2021 to 2031
Figure 61: South Asia Market Attractiveness Analysis by Distribution Channel, 2021 to 2031
Figure 62: South Asia Market Attractiveness Analysis by Country, 2021 to 2031
Figure 63: East Asia Anxiety Market Share, By Drug Molecule (2021)
Figure 64: East Asia Market Share, By Anxiety Type (2021)
Figure 65: East Asia Market Share, By Distribution Channel (2021)
Figure 66: East Asia Market Share, By Country (2021)
Figure 67: East Asia Canine Market size (US$ Mn) 2021 & 2031
Figure 68: East Asia Market Value (US$ Mn) Analysis, 2016 to 2020
Figure 69: East Asia Market Value (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 70: East Asia Market Attractiveness Analysis by Drug Molecule, 2021 to 2031
Figure 71: East Asia Market Attractiveness Analysis by Anxiety Type 2021 to 2031
Figure 72: East Asia Market Attractiveness Analysis by Distribution Channel, 2021 to 2031
Figure 73: East Asia Market Attractiveness Analysis by Country, 2021 to 2031
Figure 74: Oceania Asia Anxiety Market Share, By Drug Molecule (2021)
Figure 75: Oceania Market Share, By Anxiety Type (2021)
Figure 76: Oceania Market Share, By Distribution Channel (2021)
Figure 77: Oceania Market Share, By Country (2021)
Figure 78: Oceania Canine Market size (US$ Mn) 2021 & 2031
Figure 79: Oceania Market Value (US$ Mn) Analysis, 2016 to 2020
Figure 80: Oceania Market Value (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 81: Oceania Market Attractiveness Analysis by Drug Molecule, 2021 to 2031
Figure 82: Oceania Market Attractiveness Analysis by Anxiety Type 2021 to 2031
Figure 83: Oceania Market Attractiveness Analysis by Distribution Channel, 2021 to 2031
Figure 84: Oceania Market Attractiveness Analysis by Country, 2021 to 2031
Figure 85: Middle East & Africa Anxiety Market Share, By Drug Molecule (2021)
Figure 86: Middle East & Africa Market Share, By Anxiety Type (2021)
Figure 87: Middle East & Africa Market Share, By Distribution Channel (2021)
Figure 88: Middle East & Africa Market Share, By Country (2021)
Figure 89: Middle East & Africa Market size (US$ Mn) 2021 & 2031
Figure 90: Middle East & Africa Market Value (US$ Mn) Analysis, 2016 to 2020
Figure 91: Middle East & Africa Market Value (US$ Mn) & Y-o-Y Growth (%), 2021 to 2031
Figure 92: Middle East & Africa Market Attractiveness Analysis by Drug Molecule, 2021 to 2031
Figure 93: Middle East & Africa Market Attractiveness Analysis by Anxiety Type 2021 to 2031
Figure 94: Middle East & Africa Market Attractiveness Analysis by Distribution Channel, 2021 to 2031
Figure 95: Middle East & Africa Market Attractiveness Analysis by Country, 2021 to 2031
Figure 96: Global Vs. U.S. Growth Comparison
Figure 97: U.S. Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 98: U.S. Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 99: U.S. Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 100: Global Vs. Canada Growth Comparison
Figure 101: Canada Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 102: U.S. Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 103: U.S. Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 104: Global Vs. Brazil Growth Comparison
Figure 105: Brazil Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 106: Brazil Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 107: Brazil Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 108: Global Vs. Mexico Growth Comparison
Figure 109: Mexico Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 110: Mexico Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 111: Mexico Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 112: Global Vs. Argentina Growth Comparison
Figure 113: Argentina Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 114: Argentina Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 115: Argentina Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 116: Global Vs. U.K. Growth Comparison
Figure 117: U.K. Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 118: U.K. Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 119: U.K. Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 120: Global Vs. Germany Growth Comparison
Figure 121: Germany Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 122: Germany Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 123: Germany Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 124: Global Vs. France Growth Comparison
Figure 125: France Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 126: France Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 127: France Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 128: Global Vs. Italy Growth Comparison
Figure 129: Italy Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 130: Italy Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 131: Italy Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 132: Global Vs. Spain Growth Comparison
Figure 133: Spain Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 134: Spain Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 135: Spain Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 136: Global Vs. Russia Growth Comparison
Figure 137: Russia Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 138: Russia Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 139: Russia Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 140: Global Vs. BENELUX Growth Comparison
Figure 141: BENELUX Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 142: BENELUX Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 143: BENELUX Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 144: Global Vs. India Growth Comparison
Figure 145: India Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 146: India Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 147: India Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 148: Global Vs. Malaysia Growth Comparison
Figure 149: Malaysia Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 150: Malaysia Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 151: Malaysia Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 152: Global Vs. Thailand Growth Comparison
Figure 153: Thailand Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 154: Thailand Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 155: Thailand Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 156: Global Vs. Indonesia Growth Comparison
Figure 157: Indonesia Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 158: Indonesia Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 159: Indonesia Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 160: Global Vs. China Growth Comparison
Figure 161: China Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 162: China Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 163: China Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 164: Global Vs. Japan Growth Comparison
Figure 165: Japan Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 166: Japan Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 167: Japan Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 168: Global Vs. Australia Growth Comparison
Figure 169: Australia Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 170: Australia Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 171: Australia Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 172: Global Vs. New Zealand Growth Comparison
Figure 173: New Zealand Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 174: New Zealand Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 175: New Zealand Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 176: Global Vs. South Africa Growth Comparison
Figure 177: South Africa Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 178: South Africa Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 179: South Africa Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 180: Global Vs. Turkey Growth Comparison
Figure 181: Turkey Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 182: Turkey Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 183: Turkey Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
Figure 184: Global Vs. GCC Countries Growth Comparison
Figure 185: GCC Countries Anxiety Analysis (%) By Drug Molecule, 2021 & 2031
Figure 186: GCC Countries Anxiety Analysis (%) By Anxiety Type, 2021 & 2031
Figure 187: GCC Countries Anxiety Analysis (%) By Distribution Channel, 2021 & 2031
- FAQs -
How much is the canine separation anxiety treatment market currently worth?
The global canine separation anxiety treatment market is worth at US$ 22.45, and is set to expand 2X over the next ten years.
What will be the sales forecast for canine separation anxiety treatment?
The market is expected to reach US$ 39.9 Mn by the end of 2031, with sales revenue expected to register a CAGR of close to 6% over the forecast period.
What was last 5-year market CAGR for canine separation anxiety treatment?
From 2016-2020, the canine separation anxiety treatment industry expanded at the rate of 4.3%, owing to high prevalence of canine separation anxiety disorders across regions.
What are the key trends shaping the canine separation anxiety treatment space?
Growing preference for pet Insurance, demand for generic drugs, and market consolidation are some of the key trends in this market space.
Which are the top 5 countries driving demand for canine separation anxiety treatment?
The U.S., China, Brazil, India, and Germany are expected to drive most demand for canine separation anxiety treatment.
What is the North America market outlook for canine separation anxiety treatment?
North America is one of the key markets for canine separation anxiety treatment. According to Fact.MR, the U.S. is expected to account for over 90% of the North American market through 2031.
How is the market for canine separation anxiety treatment faring in Europe?
Demand of canine separation anxiety treatment is expected to register a growth rate of 5% in Europe over the next ten years.
Which countries are key players in canine separation anxiety treatment?
The U.S., Canada, Germany, U.K., France, and Australia are key players in this market.
Which country is a key provider of canine separation anxiety treatment?
The U.S. is one of the key providers of canine separation anxiety treatment in the world.
What are the key market statistics for Korea and Japan related to canine separation anxiety treatment?
Though Japan’s veterinary pharmaceutical market is growing slower than other developed nations, demand for canine separation anxiety treatment will exhibit growth at 7.3% CAGR. South Korea holds revenue share of 7%
Related Reports
Canine Separation Anxiety Treatment Market